ARS Pharmaceuticals
SPRY
73 hedge funds and large institutions have $425M invested in ARS Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 25 increasing their positions, 13 reducing their positions, and 13 closing their positions.
272% more capital invested
Capital invested by funds: $114M → $425M (+$311M)
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
92% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 13
92% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 13
53.34% more ownership
Funds ownership: 85.77% → 139.11% (+53%)
20% more funds holding
Funds holding: 61 → 73 (+12)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$71.9M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$19.5M |
| 3 |
SOCM
SR One Capital Management
Wayne,
Pennsylvania
|
+$19.5M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$13M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$6.6M |
| 2 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$2.44M |
| 3 |
Millennium Management
New York
|
-$2.06M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$1.71M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
-$1.04M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
T. Rowe Price Associates
Baltimore,
Maryland
| – | -$140K | -26,500 | Closed |
|
77
State of Wisconsin Investment Board
Madison,
Wisconsin
| – | -$128K | -24,200 | Closed |
|
|
OQS
78
Occudo Quantitative Strategies
Fort Lauderdale,
Florida
| – | -$80K | -15,057 | Closed |
|
|
AC
79
Apogem Capital
New York
| – | -$73K | -13,793 | Closed |
|
|
QFA
80
Quattro Financial Advisors
The Woodlands,
Texas
| – | -$68K | -12,869 | Closed |
|
|
TSS
81
Two Sigma Securities
New York
| – | -$67K | -12,740 | Closed |
|
|
SSA
82
Schonfeld Strategic Advisors
New York
| – | -$62K | -11,600 | Closed |
|
83
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$12K | -2,220 | Closed |
|
84
BNP Paribas Financial Markets
Paris,
France
| – | -$2.41K | -456 | Closed |
|
85
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$32 | +5 | New |
|
SPRY Hedge Fund Activity: Q4 2022 in Review
73 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q4 2022, worth a combined $425M — up 272% from $114M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new SPRY positions and 13 closed out — a net gain of 12 holders — while 25 added to existing stakes and 13 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $71.9M. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $6.6M sold.
- 73 institutional investors held ARS Pharmaceuticals (SPRY) as of Q4 2022, up from 61 in Q3 2022.
- Funds reported $425M of ARS Pharmaceuticals stock for Q4 2022, up 272% quarter-over-quarter.
- 25 funds opened new ARS Pharmaceuticals positions in Q4 2022 and 13 closed out, a net change of +12 holders.
- The largest ARS Pharmaceuticals buyer in Q4 2022 was Deerfield Management, an estimated $71.9M added.
- The largest ARS Pharmaceuticals seller in Q4 2022 was Nantahala Capital Management, an estimated $6.6M sold.
Based on aggregated 13F filings for Q4 2022.